Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
DISHMAN PHARMA | BIOCON | DISHMAN PHARMA/ BIOCON |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 34.9 | 71.9% | View Chart |
P/BV | x | 3.3 | 4.4 | 75.6% | View Chart |
Dividend Yield | % | 0.7 | 0.2 | 298.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
BIOCON Mar-19 |
DISHMAN PHARMA/ BIOCON |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 707 | 52.9% | |
Low | Rs | 129 | 554 | 23.3% | |
Sales per share (Unadj.) | Rs | 197.8 | 91.9 | 215.2% | |
Earnings per share (Unadj.) | Rs | 21.2 | 16.7 | 126.9% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 24.2 | 143.6% | |
Dividends per share (Unadj.) | Rs | 2.00 | 1.00 | 200.0% | |
Dividend yield (eoy) | % | 0.8 | 0.2 | 501.1% | |
Book value per share (Unadj.) | Rs | 179.9 | 101.6 | 177.0% | |
Shares outstanding (eoy) | m | 80.69 | 600.00 | 13.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 6.9 | 18.5% | |
Avg P/E ratio | x | 11.9 | 37.7 | 31.4% | |
P/CF ratio (eoy) | x | 7.2 | 26.1 | 27.8% | |
Price / Book Value ratio | x | 1.4 | 6.2 | 22.5% | |
Dividend payout | % | 9.4 | 6.0 | 157.6% | |
Avg Mkt Cap | Rs m | 20,306 | 378,330 | 5.4% | |
No. of employees | `000 | 0.8 | 6.1 | 13.5% | |
Total wages/salary | Rs m | 5,355 | 11,653 | 46.0% | |
Avg. sales/employee | Rs Th | 19,252.7 | 8,994.3 | 214.1% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,900.7 | 339.9% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 1,635.3 | 126.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 55,144 | 28.9% | |
Other income | Rs m | 265 | 1,444 | 18.4% | |
Total revenues | Rs m | 16,226 | 56,588 | 28.7% | |
Gross profit | Rs m | 4,103 | 15,883 | 25.8% | |
Depreciation | Rs m | 1,091 | 4,478 | 24.4% | |
Interest | Rs m | 944 | 709 | 133.2% | |
Profit before tax | Rs m | 2,334 | 12,140 | 19.2% | |
Minority Interest | Rs m | 0 | 9 | 0.0% | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 2,123 | 29.4% | |
Profit after tax | Rs m | 1,711 | 10,026 | 17.1% | |
Gross profit margin | % | 25.7 | 28.8 | 89.3% | |
Effective tax rate | % | 26.7 | 17.5 | 152.8% | |
Net profit margin | % | 10.7 | 18.2 | 59.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 48,228 | 22.8% | |
Current liabilities | Rs m | 9,517 | 30,376 | 31.3% | |
Net working cap to sales | % | 9.4 | 32.4 | 29.0% | |
Current ratio | x | 1.2 | 1.6 | 72.9% | |
Inventory Days | Days | 110 | 68 | 161.8% | |
Debtors Days | Days | 35 | 86 | 40.7% | |
Net fixed assets | Rs m | 16,304 | 64,130 | 25.4% | |
Share capital | Rs m | 161 | 3,000 | 5.4% | |
"Free" reserves | Rs m | 12,907 | 57,980 | 22.3% | |
Net worth | Rs m | 14,516 | 60,980 | 23.8% | |
Long term debt | Rs m | 4,189 | 15,766 | 26.6% | |
Total assets | Rs m | 29,805 | 121,924 | 24.4% | |
Interest coverage | x | 3.5 | 18.1 | 19.2% | |
Debt to equity ratio | x | 0.3 | 0.3 | 111.6% | |
Sales to assets ratio | x | 0.5 | 0.5 | 118.4% | |
Return on assets | % | 8.9 | 8.8 | 101.2% | |
Return on equity | % | 11.8 | 16.4 | 71.7% | |
Return on capital | % | 17.5 | 16.8 | 104.6% | |
Exports to sales | % | 24.8 | 28.1 | 88.2% | |
Imports to sales | % | 3.7 | 18.9 | 19.8% | |
Exports (fob) | Rs m | 3,956 | 15,506 | 25.5% | |
Imports (cif) | Rs m | 596 | 10,399 | 5.7% | |
Fx inflow | Rs m | 4,952 | 15,506 | 31.9% | |
Fx outflow | Rs m | 697 | 10,399 | 6.7% | |
Net fx | Rs m | 4,255 | 5,107 | 83.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 11,546 | 24.1% | |
From Investments | Rs m | -1,529 | -7,138 | 21.4% | |
From Financial Activity | Rs m | -941 | -2,417 | 38.9% | |
Net Cashflow | Rs m | 316 | 2,103 | 15.0% |
Indian Promoters | % | 61.4 | 40.4 | 152.0% | |
Foreign collaborators | % | 0.0 | 20.6 | - | |
Indian inst/Mut Fund | % | 3.7 | 8.4 | 44.0% | |
FIIs | % | 12.7 | 10.7 | 118.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 19.9 | 111.1% | |
Shareholders | 46,261 | 109,995 | 42.1% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | 89,400.0% |
Compare DISHMAN PHARMA With: STRIDES PHARMA SCIENCE CADILA HEALTHCARE VENUS REMEDIES ALEMBIC PHARMA GLENMARK PHARMA
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More